Stroke trial shows promise of UK stem cell sector
This article was originally published in Clinica
The first stem cell clinical trial to receive UK approval has begun, in a patient left disabled by an ischaemic stroke (www.clinica.co.uk, 16 November 2010). If the trial is successful – and we won't know the results for some time – it will be good news not only for the patients in the trial and the company supplying the cells, but for the whole area of UK stem cell research – and biotech investors too.
You may also be interested in...
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.